PROPHYLACTIC USE OF FLUCONAZOLE IN NEUTROPENIC CANCER-PATIENTS


Creative Commons License

YAMAC K., SENOL E., HAZNEDAR R.

POSTGRADUATE MEDICAL JOURNAL, cilt.71, sa.835, ss.284-286, 1995 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 71 Konu: 835
  • Basım Tarihi: 1995
  • Doi Numarası: 10.1136/pgmj.71.835.284
  • Dergi Adı: POSTGRADUATE MEDICAL JOURNAL
  • Sayfa Sayıları: ss.284-286

Özet

This study was carried out on 70 patients with haematological or solid malignancies who were receiving chemotherapy and/or radiotherapy. Forty-one patients were randomly assigned to receive fluconazole, 400 mg/day, while they were neutropenic. Systemic fungal infection developed in four of the 41 patients (9%) receiving prophylaxis in comparison to nine of 29 patients (31%) not receiving prophylaxis. The incidence of systemic fungal infection was significantly different between the groups receiving prophylaxis and those not receiving it (p < 0.05). Fluconazole was found to be effective for preventing systemic fungal infections in neutropenic patients with cancer.